|

A Study to Evaluate ALN-4324 on Insulin Sensitivity in Adults With Type 2 Diabetes Mellitus

RECRUITINGPhase 2Sponsored by Alnylam Pharmaceuticals
Actively Recruiting
PhasePhase 2
SponsorAlnylam Pharmaceuticals
Started2026-01-15
Est. completion2027-05-28
Eligibility
Age18 Years – 65 Years
Healthy vol.Accepted
Locations1 site
View on ClinicalTrials.gov →

NCT07465224

Summary

The purpose of this study is to evaluate the effect of a single dose of ALN-4324 on whole-body insulin sensitivity in participants with T2DM

Eligibility

Age: 18 Years – 65 YearsHealthy volunteers accepted
Inclusion Criteria:

* Is an adult patient with a confirmed diagnosis of T2DM
* Has a body mass index (BMI) of ≥25 kg/m\^2 and \<39.9 kg/m\^2
* Has a hemoglobin A1c (HbA1c) ≥6.5% to \<10.5%
* Is on a stable dose of metformin

Exclusion Criteria:

* Has any clinically significant concomitant disease, medical condition, or abnormal laboratory finding that could compromise participant safety or confound interpretation of study results
* Receiving therapies known to interfere with glucose or insulin metabolism other than current treatment for T2DM or birth control methods

Note: other protocol defined inclusion/exclusion criteria apply

Conditions2

DiabetesType 2 Diabetes Mellitus (T2DM)

Interventions1

ALN-4324

Locations1 site

Clinical Trial Site
Chula Vista, California, 91911

Browse More Trials

Diabetes trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.